Literature DB >> 19138055

NF-kappaB-mediated HER2 overexpression in radiation-adaptive resistance.

Ning Cao1, Shiyong Li, Zhaoqing Wang, Kazi Mokim Ahmed, Michael E Degnan, Ming Fan, Joseph R Dynlacht, Jian Jian Li.   

Abstract

The molecular mechanisms governing acquired tumor resistance during radiotherapy remain to be elucidated. In breast cancer patients, overexpression of HER2 (human epidermal growth factor receptor 2) is correlated with aggressive tumor growth and increased recurrence. In the present study, we demonstrate that HER2 expression can be induced by radiation in breast cancer cells with a low basal level of HER2. Furthermore, HER2-postive tumors occur at a much higher frequency in recurrent invasive breast cancer (59%) compared to the primary tumors (41%). Interestingly, NF-kappaB is required for radiation-induced HER2 transactivation. HER2 was found to be co-activated with basal and radiation-induced NF-kappaB activity in radioresistant but not radiosensitive breast cancer cell lines after long-term radiation exposure, indicating that NF-kappaB-mediated HER2 overexpression is involved in radiation-induced repopulation in heterogeneous tumors. Finally, we found that inhibition of HER2 resensitizes the resistant cell lines to radiation. Since HER2 is shown to activate NF-kappaB, our data suggest a loop-like HER2-NF-kappaB-HER2 pathway in radiation-induced adaptive resistance in breast cancer cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19138055      PMCID: PMC2659759          DOI: 10.1667/RR1472.1

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  48 in total

1.  Effector genes altered in MCF-7 human breast cancer cells after exposure to fractionated ionizing radiation.

Authors:  Z Li; L Xia; L M Lee; A Khaletskiy; J Wang; J Y Wong; J J Li
Journal:  Radiat Res       Date:  2001-04       Impact factor: 2.841

2.  The ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis.

Authors:  X Xing; S C Wang; W Xia; Y Zou; R Shao; K Y Kwong; Z Yu; S Zhang; S Miller; L Huang; M C Hung
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

Review 3.  ErbB2 makes beta 4 integrin an accomplice in tumorigenesis.

Authors:  Senthil K Muthuswamy
Journal:  Cell       Date:  2006-08-11       Impact factor: 41.582

4.  Radiation effects on development of HER2-positive breast carcinomas.

Authors:  Fabio Castiglioni; Monica Terenziani; Maria Luisa Carcangiu; Raffaella Miliano; Piera Aiello; Lorenzo Bertola; Tiziana Triulzi; Patrizia Gasparini; Tiziana Camerini; Gabriella Sozzi; Franca Fossati-Bellani; Sylvie Ménard; Elda Tagliabue
Journal:  Clin Cancer Res       Date:  2007-01-01       Impact factor: 12.531

5.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.

Authors:  Shideng Bao; Qiulian Wu; Roger E McLendon; Yueling Hao; Qing Shi; Anita B Hjelmeland; Mark W Dewhirst; Darell D Bigner; Jeremy N Rich
Journal:  Nature       Date:  2006-10-18       Impact factor: 49.962

6.  Nuclear factor-kappaB p65 inhibits mitogen-activated protein kinase signaling pathway in radioresistant breast cancer cells.

Authors:  Kazi M Ahmed; Shaozhong Dong; Ming Fan; Jian Jian Li
Journal:  Mol Cancer Res       Date:  2006-12       Impact factor: 5.852

7.  HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway.

Authors:  B P Zhou; M C Hu; S A Miller; Z Yu; W Xia; S Y Lin; M C Hung
Journal:  J Biol Chem       Date:  2000-03-17       Impact factor: 5.157

8.  IkappaB kinase alpha kinase activity is required for self-renewal of ErbB2/Her2-transformed mammary tumor-initiating cells.

Authors:  Yixue Cao; Jun-Li Luo; Michael Karin
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-21       Impact factor: 11.205

Review 9.  NF-kappa B-mediated adaptive resistance to ionizing radiation.

Authors:  Kazi Mokim Ahmed; Jian Jian Li
Journal:  Free Radic Biol Med       Date:  2007-10-10       Impact factor: 7.376

Review 10.  Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family members.

Authors:  M A Olayioye
Journal:  Breast Cancer Res       Date:  2001-10-04       Impact factor: 6.466

View more
  68 in total

Review 1.  Strategies for combining immunotherapy with radiation for anticancer therapy.

Authors:  Steven N Seyedin; Jonathan E Schoenhals; Dean A Lee; Maria A Cortez; Xiaohong Wang; Sharareh Niknam; Chad Tang; David S Hong; Aung Naing; Padmanee Sharma; James P Allison; Joe Y Chang; Daniel R Gomez; John V Heymach; Ritsuko U Komaki; Laurence J Cooper; James W Welsh
Journal:  Immunotherapy       Date:  2015-08-27       Impact factor: 4.196

2.  Rac1 is a potential target to circumvent radioresistance.

Authors:  Wen-Ling Wang; Wei-Chien Huang
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

3.  HER2 and EGFR Overexpression Support Metastatic Progression of Prostate Cancer to Bone.

Authors:  Kathleen C Day; Guadalupe Lorenzatti Hiles; Molly Kozminsky; Scott J Dawsey; Alyssa Paul; Luke J Broses; Rajal Shah; Lakshmi P Kunja; Christopher Hall; Nallasivam Palanisamy; Stephanie Daignault-Newton; Layla El-Sawy; Steven James Wilson; Andrew Chou; Kathleen Woods Ignatoski; Evan Keller; Dafydd Thomas; Sunitha Nagrath; Todd Morgan; Mark L Day
Journal:  Cancer Res       Date:  2016-10-28       Impact factor: 12.701

4.  CDK1-Mediated SIRT3 Activation Enhances Mitochondrial Function and Tumor Radioresistance.

Authors:  Rui Liu; Ming Fan; Demet Candas; Lili Qin; Xiaodi Zhang; Angela Eldridge; June X Zou; Tieqiao Zhang; Shuaib Juma; Cuihong Jin; Robert F Li; Julian Perks; Lun-Quan Sun; Andrew T M Vaughan; Chun-Xu Hai; David R Gius; Jian Jian Li
Journal:  Mol Cancer Ther       Date:  2015-07-03       Impact factor: 6.261

Review 5.  Preclinical rationale for combining radiation therapy and immunotherapy beyond checkpoint inhibitors (i.e., CART).

Authors:  James P Flynn; Mark H O'Hara; Saumil J Gandhi
Journal:  Transl Lung Cancer Res       Date:  2017-04

Review 6.  The network of epithelial-mesenchymal transition: potential new targets for tumor resistance.

Authors:  Danupon Nantajit; Dong Lin; Jian Jian Li
Journal:  J Cancer Res Clin Oncol       Date:  2014-10-01       Impact factor: 4.553

Review 7.  Cancer stem cells and radioresistance.

Authors:  Kiera Rycaj; Dean G Tang
Journal:  Int J Radiat Biol       Date:  2014-03-07       Impact factor: 2.694

8.  HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells.

Authors:  Nadire Duru; Ming Fan; Demet Candas; Cheikh Menaa; Hsin-Chen Liu; Danupon Nantajit; Yunfei Wen; Kai Xiao; Angela Eldridge; Brett A Chromy; Shiyong Li; Douglas R Spitz; Kit S Lam; Max S Wicha; Jian Jian Li
Journal:  Clin Cancer Res       Date:  2012-10-22       Impact factor: 12.531

9.  Induction of ERBB2 nuclear transport after radiation in breast cancer cells.

Authors:  Bo Luo; Shiying Yu; Liang Zhuang; Shu Xia; Zhen Zhao; Lei Rong
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-06-10

10.  HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab.

Authors:  Suthinee Ithimakin; Kathleen C Day; Fayaz Malik; Qin Zen; Scott J Dawsey; Tom F Bersano-Begey; Ahmed A Quraishi; Kathleen Woods Ignatoski; Stephanie Daignault; April Davis; Christopher L Hall; Nallasivam Palanisamy; Amber N Heath; Nader Tawakkol; Tahra K Luther; Shawn G Clouthier; Whitney A Chadwick; Mark L Day; Celina G Kleer; Dafydd G Thomas; Daniel F Hayes; Hasan Korkaya; Max S Wicha
Journal:  Cancer Res       Date:  2013-02-26       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.